Your fact-checks will appear here
Treatment of strongyloidiasis with ivermectin
tablets for humans are marketed primarily in a 3 mg strength (with some labeling records also listing a 6 mg presentation) and are approved to treat parasitic infections using weight‑based single dose...
Ivermectin dosing for human parasitic infections is weight-based and generally expressed in micrograms per kilogram (mcg/kg); the usual therapeutic range for common infections is about 150–200 mcg/kg ...
Ivermectin dosing for human parasitic infections is weight-based, most commonly prescribed at about 200 micrograms per kilogram (mcg/kg) as a single oral dose for strongyloidiasis and many scabies reg...
tablets for humans are labeled as 3 mg each and clinical dosing is calculated by body weight, typically using 150–200 micrograms per kilogram (mcg/kg) depending on the indication; the drug label and m...
Dosing tables convert a weight-based microgram-per-kilogram (mcg/kg) into whole 3 mg tablets by multiplying patient weight (kg) by the target mcg/kg dose to get total micrograms, then dividing by 3,00...
for humans is explicitly weight‑based: recommended therapeutic regimens are expressed in micrograms or milligrams per kilogram of body weight rather than by a fixed tablet count . A single 12 mg dose ...
is rapidly absorbed and cleared from blood with an elimination half‑life in humans of roughly 12–14 hours, and modern mass‑spectrometry methods can detect low nanogram‑per‑mL concentrations in plasma/...
’s reputation as a neurotoxin rests largely on reports of overdose, rare encephalopathy in specific parasitic co‑infections, and animal data showing CNS effects at high concentrations; conversely, a s...
The FDA‑label prescribing information for STROMECTOL (ivermectin) specifies dosing by indication: a single oral dose of approximately 200 mcg/kg for intestinal strongyloidiasis and approximately 150 m...
Reports and case-series show multiple instances where people ingested veterinary ivermectin formulations — most commonly during the COVID-19 pandemic — producing a spectrum of outcomes from mild gastr...
is an approved antiparasitic with weight-based dosing and a generally favorable safety profile for labeled indications, but clinicians must take clear precautions—confirm indications, calculate weight...
Clinicians must identify or exclude high Loa loa microfilaremia before giving ivermectin in endemic areas because serious adverse events—including encephalopathy and death—are tightly linked to high c...
Ivermectin is an effective, evidence-based antiparasitic for specific human infections — notably onchocerciasis and strongyloidiasis — when used at approved doses under medical supervision . It is not...
Repeating ivermectin is routine for onchocerciasis (often yearly) and sometimes necessary for strongyloidiasis—especially in immunocompromised patients—but repetition brings predictable risks that can...